Jefferies Financial Group Inc. Makes New Investment in KORU Medical Systems, Inc. (NASDAQ:KRMD)

Jefferies Financial Group Inc. acquired a new stake in KORU Medical Systems, Inc. (NASDAQ:KRMD) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 34,300 shares of the company’s stock, valued at approximately $132,000.

Several other hedge funds also recently modified their holdings of the business. Calamos Advisors LLC acquired a new position in KORU Medical Systems during the 4th quarter valued at $250,000. White Pine Capital LLC increased its holdings in shares of KORU Medical Systems by 25.6% during the 4th quarter. White Pine Capital LLC now owns 157,917 shares of the company’s stock worth $608,000 after purchasing an additional 32,176 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in shares of KORU Medical Systems during the fourth quarter valued at about $104,000. Raymond James Financial Inc. acquired a new position in shares of KORU Medical Systems during the fourth quarter valued at about $118,000. Finally, HighTower Advisors LLC lifted its stake in shares of KORU Medical Systems by 13.0% in the fourth quarter. HighTower Advisors LLC now owns 43,400 shares of the company’s stock valued at $167,000 after buying an additional 5,000 shares during the period. 58.60% of the stock is owned by institutional investors.

KORU Medical Systems Stock Performance

NASDAQ KRMD opened at $2.95 on Monday. KORU Medical Systems, Inc. has a twelve month low of $1.86 and a twelve month high of $5.05. The company has a quick ratio of 2.37, a current ratio of 2.99 and a debt-to-equity ratio of 0.01. The stock has a market cap of $136.12 million, a P/E ratio of -11.80 and a beta of 0.39. The company’s 50-day simple moving average is $2.64 and its 200 day simple moving average is $3.41.

KORU Medical Systems (NASDAQ:KRMD) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The company had revenue of $9.64 million during the quarter, compared to the consensus estimate of $8.86 million. KORU Medical Systems had a negative net margin of 37.42% and a negative return on equity of 24.60%. As a group, research analysts forecast that KORU Medical Systems, Inc. will post -0.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Piper Sandler lowered their price target on KORU Medical Systems from $4.50 to $3.50 and set a “neutral” rating on the stock in a research note on Thursday, May 8th. B. Riley raised KORU Medical Systems to a “strong-buy” rating in a report on Thursday, March 13th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $4.50.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.